Injection of Glatiramer Acetate Depot Results in T1 and T2 Lesion Reduction in Relapsing MS.

Published Date: 01 Mar 2023

Secondary results from a phase 3 study show that patients with multiple sclerosis receiving glatiramer acetate depot therapy have significantly fewer new T1 enhancing lesions and new, enlarging hyperintense T2 lesions.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

the contribution of cortactin to the development of cancer.

2.

AI Model Has Promise for Predicting Checkpoint Inhibitor Activity in NSCLC

3.

Coffee, Tea Tied to Lower Risk of Head and Neck Cancer

4.

Cancer Vaccines' Emergence; More Focus on Side Effects; A Nudge for Exercise.

5.

New tumor therapy approach reduces costs and side effects while increasing accessibility


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot